StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report report published on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Trading Up 6.8 %

Shares of Cyclacel Pharmaceuticals stock opened at $0.32 on Friday. The business has a 50-day moving average price of $0.34 and a two-hundred day moving average price of $0.54. Cyclacel Pharmaceuticals has a 1-year low of $0.29 and a 1-year high of $4.00. The company has a market cap of $2.01 million, a P/E ratio of -0.03 and a beta of 0.28.

Insiders Place Their Bets

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total transaction of $5,838,864.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 23.97% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.